Status:
COMPLETED
LYNPARZA Pancreas Cancer Japan Post-Marketing Surveillance (PMS)
Lead Sponsor:
AstraZeneca
Conditions:
Pancreatic Neoplasms
Eligibility:
All Genders
Brief Summary
To collect and characterise the incidence of adverse events related to the safety specifications of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancreatic...
Detailed Description
To collect and characterise the incidence of adverse events related to the safety specifications\*1 of the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated pancrea...
Eligibility Criteria
Inclusion
- Patients who receive LYNPARZA for the first time for the maintenance treatment after platinum-based chemotherapy in patients with BRCA mutated curatively unresectable pancreas cancer after the approval date of partial change application for the additional indication (25/Dec./2020).
Exclusion
- Patients who have no treatment history with LYNPARZA
Key Trial Info
Start Date :
May 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 6 2025
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT04889404
Start Date
May 22 2021
End Date
February 6 2025
Last Update
April 15 2025
Active Locations (60)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Osaka, Lyn010001, Japan, D081FC00004
2
Research Site
Kanagawa, Lyn010003, Japan, D081FC00004
3
Research Site
Okayama, Lyn010004, Japan, D081FC00004
4
Research Site
Akita, Lyn010005, Japan, D081FC00004